HomeCompareGLFN vs JNJ

GLFN vs JNJ: Dividend Comparison 2026

GLFN yields 666666.67% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GLFN wins by $8.275235618773884e+34M in total portfolio value
10 years
GLFN
GLFN
● Live price
666666.67%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8.275235618773884e+34M
Annual income
$82,727,945,429,218,320,000,000,000,000,000,000,000,000.00
Full GLFN calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — GLFN vs JNJ

📍 GLFN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGLFNJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GLFN + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GLFN pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GLFN
Annual income on $10K today (after 15% tax)
$56,666,666.67/yr
After 10yr DRIP, annual income (after tax)
$70,318,753,614,835,575,000,000,000,000,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, GLFN beats the other by $70,318,753,614,835,575,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GLFN + JNJ for your $10,000?

GLFN: 50%JNJ: 50%
100% JNJ50/50100% GLFN
Portfolio after 10yr
$4.137617809386942e+34M
Annual income
$41,363,972,714,609,160,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.97%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

GLFN
No analyst data
Altman Z
-327.9
Piotroski
2/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GLFN buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGLFNJNJ
Forward yield666666.67%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$8.275235618773884e+34M$30.3K
Annual income after 10y$82,727,945,429,218,320,000,000,000,000,000,000,000,000.00$4,689.40
Total dividends collected$8.275075881065991e+34M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: GLFN vs JNJ ($10,000, DRIP)

YearGLFN PortfolioGLFN Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$66,677,367$66,666,666.67$10,592$272.30+$66.67MGLFN
2$415,506,651,117$415,435,306,334.37$11,289$357.73+$415506.64MGLFN
3$2,419,908,598,386,268$2,419,464,006,269,573.00$12,123$472.89+$2419908598.37MGLFN
4$13,171,697,643,084,456,000$13,169,108,340,884,183,000.00$13,141$629.86+$13171697643084.44MGLFN
5$67,004,927,492,790,120,000,000$66,990,833,776,312,020,000,000.00$14,408$846.81+$67004927492790120.00MGLFN
6$318,562,277,003,514,840,000,000,000$318,490,581,731,097,560,000,000,000.00$16,021$1,151.60+$318562277003514871808.00MGLFN
7$1,415,484,168,853,553,000,000,000,000,000$1,415,143,307,217,159,200,000,000,000,000.00$18,122$1,588.22+$1.415484168853553e+24MGLFN
8$5,878,130,573,362,507,000,000,000,000,000,000$5,876,616,005,301,833,000,000,000,000,000,000.00$20,930$2,228.20+$5.878130573362507e+27MGLFN
9$22,813,793,009,840,743,000,000,000,000,000,000,000$22,807,503,410,127,248,000,000,000,000,000,000,000.00$24,792$3,191.91+$2.2813793009840744e+31MGLFN
10$82,752,356,187,738,840,000,000,000,000,000,000,000,000$82,727,945,429,218,320,000,000,000,000,000,000,000,000.00$30,274$4,689.40+$8.275235618773884e+34MGLFN

GLFN vs JNJ: Complete Analysis 2026

GLFNStock

McHenry Metals Golf Corp. engages in the design, development, and marketing of golf clubs. The company's TourPure product line includes five drivers and six fairway woods. Left-handed versions of the driver were designed in two models and shorter shafts and smaller grips were made available for ladies clubs. The TourPure driver's proprietary Tungsten Power Ring produces launch angles and reduces backspin, resulting in roll and distance down the fairway. Its distribution channels include the industry's retail channel of off-course golf specialty stores and on-course golf shops; on-course product demonstrations; direct response marketing through television infomercials; direct response catalogs; outbound telemarketing; e-commerce through Internet 'e-tailers' and the company's proprietary Web site (www.mchenrymetals.com); and distributors with domestic and international accounts. Its competitors include Callaway Golf Company, TaylorMade-adidas Golf Company, Acushnet, Ping, Wilson, and Spalding. The company is based in Carlsbad, California.

Full GLFN Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this GLFN vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GLFN vs SCHDGLFN vs JEPIGLFN vs OGLFN vs KOGLFN vs MAINGLFN vs ABBVGLFN vs MRKGLFN vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.